Literature DB >> 21987457

DCE-MRI model selection for investigating disruption of microvascular function in livers with metastatic disease.

Anita Banerji1, Josephine H Naish, Yvonne Watson, Gordon C Jayson, Giovanni A Buonaccorsi, Geoffrey J M Parker.   

Abstract

PURPOSE: To evaluate the Akaike information criterion (AIC) model selection technique as a method for detecting differences in microvascular characteristics between tumorous and non-tumor liver tissue.
MATERIALS AND METHODS: The AIC was applied to six patient datasets with liver metastases to determine, on a per voxel basis, which of two physiologically plausible candidate models gave a more appropriate description of the data. The dual-input single-compartment Materne model, extended to incorporate a novel portal input function estimation method, was chosen to represent liver tissue and the single-input dual-compartment extended Kety model was used for tumor.
RESULTS: Median AIC probabilities when comparing tumor versus liver and tumor versus tumor-margins were significantly different (P ≤ 0.01) in five of the six patient datasets. Comparisons between tumor margins and liver regions were significantly different in four datasets. Median AIC probabilities selected for the extended Kety model in all tumor regions, with the Materne model being progressively more probable through tumor margins into liver.
CONCLUSION: We present a viable method for assessing the spatially varying microvascular characteristics of tumor-bearing livers, with possible applications in lesion detection, assessment of tumor invasion, and measurement of drug efficacy.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21987457     DOI: 10.1002/jmri.22692

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  6 in total

1.  A semi-automatic method for the extraction of the portal venous input function in quantitative dynamic contrast-enhanced CT of the liver.

Authors:  Andrew B Gill; Nicholas J Hilliard; Simon T Hilliard; Martin J Graves; David J Lomas; Ashley Shaw
Journal:  Br J Radiol       Date:  2017-06-20       Impact factor: 3.039

2.  Dynamic contrast-enhanced optical imaging of in vivo organ function.

Authors:  Cyrus B Amoozegar; Tracy Wang; Matthew B Bouchard; Addason F H McCaslin; William S Blaner; Richard M Levenson; Elizabeth M C Hillman
Journal:  J Biomed Opt       Date:  2012-09       Impact factor: 3.170

3.  The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data.

Authors:  Andrew B Gill; Gayathri Anandappa; Andrew J Patterson; Andrew N Priest; Martin J Graves; Tobias Janowitz; Duncan I Jodrell; Tim Eisen; David J Lomas
Journal:  Magn Reson Imaging       Date:  2014-11-07       Impact factor: 2.546

4.  Diffusion model comparison identifies distinct tumor sub-regions and tracks treatment response.

Authors:  Damien J McHugh; Grazyna Lipowska-Bhalla; Muhammad Babur; Yvonne Watson; Isabel Peset; Hitesh B Mistry; Penny L Hubbard Cristinacce; Josephine H Naish; Jamie Honeychurch; Kaye J Williams; James P B O'Connor; Geoffrey J M Parker
Journal:  Magn Reson Med       Date:  2020-02-14       Impact factor: 4.668

5.  Correlation of radiomic features on dynamic contrast-enhanced magnetic resonance with microvessel density in hepatocellular carcinoma based on different models.

Authors:  Hongwei Liang; Chunhong Hu; Jian Lu; Tao Zhang; Jifeng Jiang; Ding Ding; Sheng Du; Shaofeng Duan
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

Review 6.  Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams.

Authors:  Igino Simonetti; Federico Bruno; Roberta Fusco; Carmen Cutolo; Sergio Venanzio Setola; Renato Patrone; Carlo Masciocchi; Pierpaolo Palumbo; Francesco Arrigoni; Carmine Picone; Andrea Belli; Roberta Grassi; Francesca Grassi; Antonio Barile; Francesco Izzo; Antonella Petrillo; Vincenza Granata
Journal:  J Pers Med       Date:  2022-07-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.